Less than a year ago, in July 2006, the FDA issued a Public Health Advisory on a birth defect found to be associated with Zoloft and other selective serotonin reuptake inhibitor antidepressants by a study
in the February 2006 New England Journal
of Medicine that found a higher
risk of a life-threatening lung disorder in infants exposed to SSRIs, stating:
"A recently published case-control study has shown that infants born to mothers who took selective serotonin reuptake inhibitors (SSRIs)